Action mechanism of insulin-mimetic vanadyl-allixin complex.
In the 21st century, there has been a dramatic worldwide increase in the prevalence of metabolic syndromes, including diabetes mellitus (DM). Several synthetic pharmaceutical agents have been developed and used for the treatment of type-2 DM; however, these compounds have several problems such as side effects, hypoglycemia, and weight gain. Therefore, new drugs are required for DM therapy. We have proposed that some vanadyl complexes function as potent insulin-mimetic and antidiabetic agents in type-1 and type-2 DM animal models. In this article, we review the possible action mechanism of insulin-mimetic and antidiabetic vanadyl complexes, focusing on a recently proposed complex, bis(allixinato)oxovanadium(IV), with respect to the insulin-signaling pathway in cultured adipocytes.
Hiromura
Makoto
M
Metallomics Research Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Sakurai
Hiromu
H
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minami-Tamakagaki-Cho, Suzuka, Mie 513-8670, Japan (phone: +81-59-340-0569; fax: +81-59-368-1271).
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D040761:Biomimetic Materials / Q000737:chemistry* / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D007328:Insulin / Q000737:chemistry*; D009942:Organometallic Compounds / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
D007004:Hypoglycemic Agents; D007328:Insulin; D009942:Organometallic Compounds; C511635:bis(allixinato)oxovanadium(IV)